🟢 Opus Genetics is trading 7.2% up in pre-market; no direct catalyst identified

Opus Genetics is trading 7.2% up at $3.72 in pre-market on October 26, versus a $3.47 previous close; no direct catalyst is established. - No October 26 company announcement was identified. - A weekend report recapped management’s investor-panel discussion of the newly approved presbyopia treatment, pipeline progress and projected cash runway into 2029, without linking it to the move. - The October 21 FDA clearance of the OPGx-RDH12 gene-therapy IND and reported chief scientific and development officer transition both predate the gain.